Clinical trials: Thyroid Gland Squamous Cell Carcinoma
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Cortical Cancer, Brain Cancer
Spectroscopy With Surface Coils and Decoupling
The purpose of this study is to obtain chemical information from part of your body without a biopsy. This is done using a technique called magnetic resonance spectroscopy (MRS) which is similar to magnetic resonance imaging (MRI)…
- Conditions
- Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer
- Trial name
- NCT00581815
- Testing
- Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
- Where
- United States
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.
- Conditions
- Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor
- Trial name
- NCT02383927
- Testing
- Tipifarnib
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 63 people
- Sponsor
- Kura Oncology, Inc.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer.
- Trial name
- NCT04675710
- Testing
- Conventional Surgery, Dabrafenib, Intensity-Modulated Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
MSI-H Colorectal Cancer, Melanoma
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
- Conditions
- MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma
- Trial name
- ACROPOLI (NCT04802876)
- Testing
- Spartalizumab, Tislelizumab
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Neoplasms
Cell-free Tumor DNA in Head and Neck Cancer Patients
This study investigates if head and neck squamous cell carcinoma can be tracked with cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion of cancer, and if it can be used in detecting…
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer
- Trial name
- NCT03942380
- Testing
- Liquid biopsy
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- Christian von Buchwald
Papillary Thyroid Carcinoma
Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?
study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central neck dissection.
- Trial name
- NCT04336696
- Testing
- Total thyroidectomy and central neck dissection
- Where
- Egypt
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bassem Mohamed Sieda
Colorectal Cancer, Head and Neck Cancer
NGR-TNF in Treating Patients With Advanced Solid Tumors
RATIONALE: Targeted therapy with tumor necrosis factor combined with a fusion protein may stop the growth of solid tumors by stopping blood flow to the tumor.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00098943
- Testing
- CNGRC peptide-TNF alpha conjugate
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Thyroid
A Gene Hunting Study for Familial Papillary Thyroid Cancer
The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability.
- Trial name
- NCT02776969
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Papillary Thyroid Cancer, Papillary Carcinoma
More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated
In absence of nodal metastases or aggressive features, thyroid lobectomy (TL) should be preferred over total thyroidectomy (TT) for small unifocal papillary thyroid carcinoma (PTC).
- Conditions
- Papillary Thyroid Cancer, Papillary Carcinoma, Thyroid Cancer, Thyroid Carcinoma
- Trial name
- cN0PTC (NCT06439745)
- Volunteers
- 314 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharynx (OPX) Biomarker Trial
The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06356272
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Mayo Clinic
Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material [deoxyribonucleic acid (DNA)]).
- Conditions
- Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT04759911
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00470496
- Testing
- HPPH, photodynamic therapy, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors…
- Conditions
- Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04119024
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Anusha Kalbasi
Thyroid Neoplasms, Carcinoma, Papillary
Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma
This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC).
- Trial name
- NCT07033572
- Testing
- Endoscopic Hemithyroidectomy with Central-Neck Dissection, Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fujian Medical University